Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiff Oncology (CRDF) Operating Expenses (2016 - 2025)

Cardiff Oncology (CRDF) has disclosed Operating Expenses for 15 consecutive years, with $8.1 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses fell 36.57% to $8.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $49.6 million through Dec 2025, changed 0.44% year-over-year, with the annual reading at $49.6 million for FY2025, 0.44% changed from the prior year.
  • Operating Expenses hit $8.1 million in Q4 2025 for Cardiff Oncology, down from $12.1 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $14.9 million in Q2 2025 to a low of $5.5 million in Q1 2021.
  • Historically, Operating Expenses has averaged $10.7 million across 5 years, with a median of $11.0 million in 2023.
  • Biggest five-year swings in Operating Expenses: soared 102.18% in 2022 and later crashed 36.57% in 2025.
  • Year by year, Operating Expenses stood at $9.7 million in 2021, then dropped by 1.44% to $9.5 million in 2022, then grew by 10.17% to $10.5 million in 2023, then rose by 21.31% to $12.7 million in 2024, then plummeted by 36.57% to $8.1 million in 2025.
  • Business Quant data shows Operating Expenses for CRDF at $8.1 million in Q4 2025, $12.1 million in Q3 2025, and $14.9 million in Q2 2025.